The United States has suspended funding for HIV treatment and prevention programmes in South Africa, a move that analysts say threatens to unravel years of progress in the global fight against the disease. The decision, confirmed by the South African health ministry on Tuesday, halts billions of dollars in aid from the President's Emergency Plan for AIDS Relief (PEPFAR), the flagship US initiative that has supported antiretroviral therapy for millions of South Africans since 2003.
South Africa, which accounts for nearly 20 per cent of the world's HIV-positive population, has long been the largest recipient of PEPFAR funding. The programme provides essential drugs, testing kits, and healthcare infrastructure to government-run clinics and community organisations. Without these resources, experts warn that treatment interruptions could lead to a resurgence of AIDS-related deaths and new infections.
The suspension, effective immediately, affects approximately 2.7 million South Africans currently receiving antiretroviral therapy through PEPFAR-supported facilities. The US State Department has not commented on the duration of the halt or the reasons behind it, though diplomatic sources suggest the move is tied to a broader review of foreign aid allocations under the current administration. South African officials have expressed dismay, with Health Minister Dr. Zweli Mkhize calling the decision "a grave setback for public health."
The financial impact is substantial. PEPFAR disbursed $480 million to South Africa in the 2023 fiscal year, covering roughly one-third of the country's HIV treatment budget. The suspension forces the South African government to seek emergency funding from domestic sources or international partners, including the Global Fund to Fight AIDS, Tuberculosis and Malaria. However, the Global Fund itself faces funding shortfalls, raising questions about whether alternative support can be mobilised quickly enough to prevent service disruptions.
Global health advocates have condemned the move. Dr. Anthony Fauci, former director of the National Institute of Allergy and Infectious Diseases, described the suspension as "catastrophic" in a statement to the Financial Times. He noted that treatment interruptions not only endanger individual patients but also increase the risk of drug-resistant strains of HIV developing. The Joint United Nations Programme on HIV/AIDS (UNAIDS) has called for an immediate reversal, warning that the decision could set back global HIV targets by a decade.
The suspension comes at a critical juncture. South Africa had been making steady progress toward the UNAIDS 95-95-95 targets, with 78 per cent of people living with HIV on antiretroviral therapy. Loss of US funding threatens to halt this trajectory, particularly among vulnerable populations such as pregnant women, who receive medication to prevent mother-to-child transmission. Without PEPFAR support, clinics in rural areas may struggle to maintain cold chains for medicines or retain trained healthcare workers.
Geopolitically, the decision strains US-South Africa relations at a time of increased cooperation on other health issues, including pandemic preparedness. South Africa is a key voice in global health governance, and its treatment programmes serve as a model for other African nations. A prolonged funding gap could erode trust in US commitments and prompt recipient countries to seek alternative partnerships, particularly with China, which has expanded its health diplomacy on the continent.
The long-term implications are severe. Without sustained investment, the region could see a reversal of the gains made since the peak of the AIDS crisis in the early 2000s. For now, the South African government is scrambling to maintain services. But as Dr. Mkhize noted, "No country can absorb a shock of this magnitude without consequences."
This is a developing story. Further updates will follow as more details emerge about the scope and duration of the funding suspension.
